Procter & Gamble Price Prediction: The Stock Eyes 10% Upside

Procter & Gamble (NYSE:PG | PG Price Prediction) is trading at $145.16 as of writing, sitting 13.3% below its 52-week high of $167.46 and well under its 50-day moving average of $153.01. Our proprietary model sees a clear path back toward fair value from here.

Our price target for Procter & Gamble is $160.50, implying 10.57% upside from current levels. The model’s recommendation is buy, backed by a 90% confidence score. Procter & Gamble carries durable cash flows, a long dividend record, and a valuation that has reset after a year of underperformance.

A Year of Pressure, But the Selloff Has Created an Entry Point

Procter & Gamble shares have declined 8.81% over the past year, with a sharper 5.32% drop in just the past month. The stock bounced 1.43% in the most recent week, suggesting stabilization near current levels. Year-to-date, shares are up 2%, masking a volatile ride from a February peak near $159.55 back down to current levels.

Q2 FY26 delivered a 1.24% core EPS beat at $1.88 versus the $1.856 consensus, but revenue of $22.208B missed the $22.289B estimate by 0.37%. Operating income fell 6.53% year-over-year, pressured by approximately $400M in after-tax tariff costs.

The Bull Case: Segment Strength and Dividend Durability

Beauty and Health Care continue posting strong results, with Beauty growing 5% organically and Health Care growing 5% organically in Q2 FY26. The company’s restructuring, which includes up to 7,000 non-manufacturing overhead reductions by end FY27, should convert into margin recovery once tariff headwinds ease.

Procter & Gamble has raised its dividend for 69 consecutive years and paid dividends for 135 consecutive years dating back to 1890. The company plans to return approximately $10B in dividends and $5B in buybacks in FY26.

Bank of America maintained a Buy rating with a $167 price target as of April 10, 2026, while UBS maintained a Buy with a $166 target. The consensus analyst target sits at $164.95, with 14 buy or strong buy ratings. Our bull case scenario projects $174.33 by April 2027.

The Bear Case: Tariffs, Volume, and Weak Baby Segment

Three pressure points threaten the thesis. First, tariff costs remain a real drag, quantified at approximately $400M in after-tax tariff costs for FY26, and any escalation could pressure the core EPS guidance range of $6.83 to $7.09.

Second, volume trends are soft. Q2 FY26 saw a 1% unit volume decline, and the Baby, Feminine and Family Care segment posted -3% organic growth.

Third, the RSI of 44.27 signals the stock has not yet found a technical floor. Piper Sandler cut its target to $142 with a Neutral rating on April 8, 2026, implying further downside. Our bear case scenario lands at $149.25.

The operating and net income declines in Q2 FY26 are largely explained by tariff headwinds and a $250M after-tax headwind from higher net interest expense and tax rates.

The Dividend King at a Discount

The price target of $160.50 reflects a business temporarily pressured by tariffs but structurally sound. I hold a 90% confidence in this target. The low beta of 0.403 means this stock won’t make you rich overnight, but it also won’t crater in a downturn. The 2.85% dividend yield provides a cushion while you wait for the re-rating.

The key variables to watch: tariff cost stabilization at current guidance and sustained organic growth in Beauty and Health Care into Q3 FY26. Further volume deterioration or a guidance cut in the April 24 earnings report would represent a meaningful downside risk to the thesis.

These projections assume Procter & Gamble continues executing on productivity and premiumization while tariff headwinds normalize. Significant upside could come from accelerated restructuring savings and Beauty or Health Care outperformance. Downside risk centers on sustained volume pressure and escalation in global trade costs.